Using IL-2 as a marker for T-cell immunoreactivity after in vitro gluten stimulation is promising, particularly in patients already on GFD, but has not yet been studied in more difficult to diagnose CD patients such as snCD or potential CD. This evidence concerns the gene IL2 and Cowden disease.